Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Tolerability of Ammoxetine in Healthy Chinese Subjects
NCT03850834Phase 1Unknown
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Mar 2019
- Primary completion
- May 2019
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial in major depressive disorder (MDD) comparing Ammoxetine with Placebo (2 arms). Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 15 days, Area under the plasma concentration time curve at 11 days and 2 more. Status: unknown.
02
Drugs
ammoxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03850834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03850834.